Single-Molecule hsTnI and Short-Term Risk in Stable Patients With Chest Pain

PROMISE Investigators

    Research output: Contribution to journalArticle

    7 Citations (Scopus)

    Abstract

    Background: Evaluation of stable symptomatic outpatients with suspected coronary artery disease (CAD) may be challenging because they have a wide range of cardiovascular risk. The role of troponin testing to assist clinical decision making in this setting is unexplored. Objectives: This study sought to evaluate the prognostic meaning of single-molecule counting high-sensitivity troponin I (hsTnI) (normal range <6 ng/l) among outpatients with stable chest symptoms and suspected CAD. Methods: Participants with available blood samples in PROMISE (Prospective Multicenter Imaging Study for Evaluation of Chest Pain) were studied, and hsTnI results were analyzed relative to the primary outcome of death, acute myocardial infarction (MI), or hospitalization for unstable angina by 1 year. The secondary outcome was the composite of cardiovascular death or acute MI. Results: The study sample consisted of 4,021 participants; 98.6% had measurable hsTnI concentrations. The median hsTnI value was 1.6 ng/l. In upper hsTnI quartiles, patients had higher-risk clinical profiles. Higher hsTnI concentrations were associated with greater event probabilities for death, acute MI, or hospitalization for unstable angina. In multivariable models, hsTnI concentrations independently predicted death, acute MI, or hospitalization for unstable angina (hazard ratio: 1.54 per increase in log-hsTnI interquartile range; p < 0.001) and cardiovascular death or acute MI (hazard ratio: 1.52 per increase in log-hsTnI interquartile range; p < 0.001) and were particularly associated with near-term events, compared with longer follow-up. Conclusions: In symptomatic outpatients with suspected CAD, higher concentrations of hsTnI within the normal range were associated with heightened near-term risk for death, acute MI, or hospitalization. (Prospective Multicenter Imaging Study for Evaluation of Chest Pain [PROMISE]; NCT01174550)

    Original languageEnglish (US)
    Pages (from-to)251-260
    Number of pages10
    JournalJournal of the American College of Cardiology
    Volume73
    Issue number3
    DOIs
    StatePublished - Jan 29 2019

    Fingerprint

    Troponin I
    Chest Pain
    Myocardial Infarction
    Unstable Angina
    Hospitalization
    Coronary Artery Disease
    Outpatients
    Multicenter Studies
    Reference Values
    Troponin
    Thorax

    Keywords

    • chest pain
    • stable angina
    • troponin

    ASJC Scopus subject areas

    • Cardiology and Cardiovascular Medicine

    Cite this

    Single-Molecule hsTnI and Short-Term Risk in Stable Patients With Chest Pain. / PROMISE Investigators.

    In: Journal of the American College of Cardiology, Vol. 73, No. 3, 29.01.2019, p. 251-260.

    Research output: Contribution to journalArticle

    @article{166e46d6ceca4ff99a3775998ff76709,
    title = "Single-Molecule hsTnI and Short-Term Risk in Stable Patients With Chest Pain",
    abstract = "Background: Evaluation of stable symptomatic outpatients with suspected coronary artery disease (CAD) may be challenging because they have a wide range of cardiovascular risk. The role of troponin testing to assist clinical decision making in this setting is unexplored. Objectives: This study sought to evaluate the prognostic meaning of single-molecule counting high-sensitivity troponin I (hsTnI) (normal range <6 ng/l) among outpatients with stable chest symptoms and suspected CAD. Methods: Participants with available blood samples in PROMISE (Prospective Multicenter Imaging Study for Evaluation of Chest Pain) were studied, and hsTnI results were analyzed relative to the primary outcome of death, acute myocardial infarction (MI), or hospitalization for unstable angina by 1 year. The secondary outcome was the composite of cardiovascular death or acute MI. Results: The study sample consisted of 4,021 participants; 98.6{\%} had measurable hsTnI concentrations. The median hsTnI value was 1.6 ng/l. In upper hsTnI quartiles, patients had higher-risk clinical profiles. Higher hsTnI concentrations were associated with greater event probabilities for death, acute MI, or hospitalization for unstable angina. In multivariable models, hsTnI concentrations independently predicted death, acute MI, or hospitalization for unstable angina (hazard ratio: 1.54 per increase in log-hsTnI interquartile range; p < 0.001) and cardiovascular death or acute MI (hazard ratio: 1.52 per increase in log-hsTnI interquartile range; p < 0.001) and were particularly associated with near-term events, compared with longer follow-up. Conclusions: In symptomatic outpatients with suspected CAD, higher concentrations of hsTnI within the normal range were associated with heightened near-term risk for death, acute MI, or hospitalization. (Prospective Multicenter Imaging Study for Evaluation of Chest Pain [PROMISE]; NCT01174550)",
    keywords = "chest pain, stable angina, troponin",
    author = "{PROMISE Investigators} and Januzzi, {James L.} and Sunil Suchindran and Udo Hoffmann and Patel, {Manesh R.} and Maros Ferencik and Adrian Coles and Tardif, {Jean Claude} and Ginsburg, {Geoffrey S.} and Douglas, {Pamela S.}",
    year = "2019",
    month = "1",
    day = "29",
    doi = "10.1016/j.jacc.2018.10.065",
    language = "English (US)",
    volume = "73",
    pages = "251--260",
    journal = "Journal of the American College of Cardiology",
    issn = "0735-1097",
    publisher = "Elsevier USA",
    number = "3",

    }

    TY - JOUR

    T1 - Single-Molecule hsTnI and Short-Term Risk in Stable Patients With Chest Pain

    AU - PROMISE Investigators

    AU - Januzzi, James L.

    AU - Suchindran, Sunil

    AU - Hoffmann, Udo

    AU - Patel, Manesh R.

    AU - Ferencik, Maros

    AU - Coles, Adrian

    AU - Tardif, Jean Claude

    AU - Ginsburg, Geoffrey S.

    AU - Douglas, Pamela S.

    PY - 2019/1/29

    Y1 - 2019/1/29

    N2 - Background: Evaluation of stable symptomatic outpatients with suspected coronary artery disease (CAD) may be challenging because they have a wide range of cardiovascular risk. The role of troponin testing to assist clinical decision making in this setting is unexplored. Objectives: This study sought to evaluate the prognostic meaning of single-molecule counting high-sensitivity troponin I (hsTnI) (normal range <6 ng/l) among outpatients with stable chest symptoms and suspected CAD. Methods: Participants with available blood samples in PROMISE (Prospective Multicenter Imaging Study for Evaluation of Chest Pain) were studied, and hsTnI results were analyzed relative to the primary outcome of death, acute myocardial infarction (MI), or hospitalization for unstable angina by 1 year. The secondary outcome was the composite of cardiovascular death or acute MI. Results: The study sample consisted of 4,021 participants; 98.6% had measurable hsTnI concentrations. The median hsTnI value was 1.6 ng/l. In upper hsTnI quartiles, patients had higher-risk clinical profiles. Higher hsTnI concentrations were associated with greater event probabilities for death, acute MI, or hospitalization for unstable angina. In multivariable models, hsTnI concentrations independently predicted death, acute MI, or hospitalization for unstable angina (hazard ratio: 1.54 per increase in log-hsTnI interquartile range; p < 0.001) and cardiovascular death or acute MI (hazard ratio: 1.52 per increase in log-hsTnI interquartile range; p < 0.001) and were particularly associated with near-term events, compared with longer follow-up. Conclusions: In symptomatic outpatients with suspected CAD, higher concentrations of hsTnI within the normal range were associated with heightened near-term risk for death, acute MI, or hospitalization. (Prospective Multicenter Imaging Study for Evaluation of Chest Pain [PROMISE]; NCT01174550)

    AB - Background: Evaluation of stable symptomatic outpatients with suspected coronary artery disease (CAD) may be challenging because they have a wide range of cardiovascular risk. The role of troponin testing to assist clinical decision making in this setting is unexplored. Objectives: This study sought to evaluate the prognostic meaning of single-molecule counting high-sensitivity troponin I (hsTnI) (normal range <6 ng/l) among outpatients with stable chest symptoms and suspected CAD. Methods: Participants with available blood samples in PROMISE (Prospective Multicenter Imaging Study for Evaluation of Chest Pain) were studied, and hsTnI results were analyzed relative to the primary outcome of death, acute myocardial infarction (MI), or hospitalization for unstable angina by 1 year. The secondary outcome was the composite of cardiovascular death or acute MI. Results: The study sample consisted of 4,021 participants; 98.6% had measurable hsTnI concentrations. The median hsTnI value was 1.6 ng/l. In upper hsTnI quartiles, patients had higher-risk clinical profiles. Higher hsTnI concentrations were associated with greater event probabilities for death, acute MI, or hospitalization for unstable angina. In multivariable models, hsTnI concentrations independently predicted death, acute MI, or hospitalization for unstable angina (hazard ratio: 1.54 per increase in log-hsTnI interquartile range; p < 0.001) and cardiovascular death or acute MI (hazard ratio: 1.52 per increase in log-hsTnI interquartile range; p < 0.001) and were particularly associated with near-term events, compared with longer follow-up. Conclusions: In symptomatic outpatients with suspected CAD, higher concentrations of hsTnI within the normal range were associated with heightened near-term risk for death, acute MI, or hospitalization. (Prospective Multicenter Imaging Study for Evaluation of Chest Pain [PROMISE]; NCT01174550)

    KW - chest pain

    KW - stable angina

    KW - troponin

    UR - http://www.scopus.com/inward/record.url?scp=85059764494&partnerID=8YFLogxK

    UR - http://www.scopus.com/inward/citedby.url?scp=85059764494&partnerID=8YFLogxK

    U2 - 10.1016/j.jacc.2018.10.065

    DO - 10.1016/j.jacc.2018.10.065

    M3 - Article

    C2 - 30678753

    AN - SCOPUS:85059764494

    VL - 73

    SP - 251

    EP - 260

    JO - Journal of the American College of Cardiology

    JF - Journal of the American College of Cardiology

    SN - 0735-1097

    IS - 3

    ER -